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Abstract
Background: We performed a meta-analysis to clarify whether the molecular detection of tumor cells or
micrometastases in the lymph node (LN) indicates a high risk of disease recurrence and poor survival in
negative pathologic lymph node status non-small cell lung cancer (NSCLC).
Methods: A literature search was performed using relevant keywords. We searched relevant studies from PubMed,
Embase, and the Cochrane Library. Direct and indirect meta-estimates were generated using Review Manager software
with fixed effects for the study. Study-to-study heterogeneity was summarized using I2 statistics and predictive
intervals (PIs).
Results: Our analysis of eight eligible studies revealed that patients with lymph node micrometastases
(LNMM) were associated with poor overall survival (OS) (HR, 1.98; 95 % CI, 1.50 to 2.62; p < 0.00001) and
disease-free survival (DFS) (HR, 2.34; 95 % CI, 1.67-3.27; p < 0.00001).
Conclusion: LNMM is associated with an increased risk of disease recurrence and poor survival in patients
with negative pathologic node negative NSCLC. Thus, these patients need to be carefully followed up after
the initial pulmonary resection.
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Background
Lung cancer is the leading cause of cancer deaths world-
wide, constituting 18 % of all cancer-related deaths. Up
to 80–85 % of lung cancers are classified as non–small-
cell lung cancer (NSCLC) [1]. Surgical treatment is an
important therapy for early-stage non-small cell lung
cancer (NSCLC). The extent of disease in NSCLC is
staged according to the TNM classification [2], and be-
cause the stage at diagnosis is the principal prognostic
indicator, accurate staging is essential for treatment
decisions.
In theory, patients with early-stage non-small cell lung
cancer can be cured by surgical resection alone. However,
approximately 30 % of patients with pathologic stage 1
NSCLC have a recurrence of the tumor and die, despite
complete surgical resection [3, 4]. This poor prognosis
suggests the occurrence of micrometastasis, which often
occurs before the primary operation and therefore cannot
be assessed by routine clinical examinations and conven-
tional histopathologic methods after the cancer has
already spread to the regional lymph nodes. The detection
of occult disease could help to identify those patients with
lymph nodes micrometastases NSCLC who are at high
risk for tumor recurrence and who might benefit from ad-
juvant therapy. Therefore, for an accurate prediction of
prognosis, it is necessary to assess the lymph node status
and to characterize micrometastasis.
The prognostic value of molecular tumor cell detection
in patients with lymph node micrometastases NSCLC re-
mains uncertain. To clarify this issue, we conducted a
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systematic review with meta-analyses of studies that evalu-
ated the prognostic significance of molecular tumor cell
detection in lymph nodes.
Methods
Search strategy
We performed a systematic search to identify articles
published after 1996 that described the association be-
tween lymph node micrometastases of NSCLC and post-
operative survival. Publications were included if they
provided the most up-to-date analysis of at least one of
the above-mentioned end points of interest. A literature
search of Medline was performed using PubMed to
identify published studies using the search terms
(“lymph nodes micrometastases” OR “micrometastases”)
AND (“non–small-cell lung cancer” OR “adenocarcin-
oma” OR “lung cancer”).
Before the beginning of this study, a rigorous protocol
was developed according to the recommendations of the
Cochrane Collaboration. The content of the documents
identified by the search were then scrutinized by two
researchers to determine eligibility for inclusion in the
meta-analysis. All documents were included in our
meta-analysis that evaluated the association of LNMM
with disease-free survival (DFS) and overall survival
(OS) of patients with negative pathologic node-negative
NSCLC. The exclusion criteria were as follows: case re-
port, clinical trials, letters to the editor and reviews with-
out evaluation of the association of LNMM with overall
survival (OS), and disease-free survival (DFS) of patients.
Data from the included documents were entered into an
electronic spreadsheet for analysis.
Statistical analysis
Synchronized extraction results were pooled statistically
as effect estimates in meta-analyses. HRs and their cor-
responding SEs were extracted for individual time-to-
event outcome parameters of each primary study. If an
HR and the associated SE or CIs were not reported, we
approximated the HR by using the statistical data pro-
vided in the article [5, 6].
The extracted HRs were pooled by using the generic
inverse-variance method available in the Review Man-
ager software 5.2.9 (Cochrane Collaboration, Oxford,
UK). Statistical heterogeneity among the trials was eval-
uated using Cochran’s Q test (χ2 test) and the Higgins I2
statistic to determine the percentage of total variation
among studies resulting from heterogeneity. If the I2
statistic was ≤ 50 % the fixed effect model was used to
pool studies; if not, the random effects model was used.




Eight eligible articles were analyzed [8–15]. All included
documents were published between 1996 and 2011
(Tables 1 and 2). The details of the search are provided
in Fig. 1.
Impact of LNMM status on OS
The impact of LNMM status on OS was assessed with the
generic inverse-variance method available in the Review
Manager software in five documents. The analysis identi-
fied a significantly different positive correlation between
the presence of isolated tumor cells in LN at the time of
diagnosis and a shortened overall survival duration (HR,
1.98; 95 % CI, 1.50 to 2.62; p < 0.00001). There was no evi-
dence of statistical heterogeneity (I2 = 0 %, χ2 = 2.28, df = 6,
P = 0.89) (Fig. 2).
Impact of LNMM status on DFS
Only three documents reported the incidence of disease-
free recurrence. Meta-analyses confirmed the prognostic











Chun-Dong Gu LNMM IHC CK(AbAE1/A) 44 4 –60 OS I Yes
Kazuhito Dobashi LNMM IHC CK(AbAE1/A) 13.6 1-60 OS pN0 Yes
B. Passlick LNMM IHC CK NR NR OS pN0 Yes
Jakob R. Izbicki, LNMM IHC/FCM Ber-Ep-4 NR 3-40 DFS pN0 Yes
By Toshihiro Osaki LNMM IHC CK(AbAE1/A) 35.8 0.1-90.6 OS I Yes
Kosei Yasumoto LNMM IHC CK2 48.2 1-64 OS/DFS I Yes
Valerie W. Rusch LNMM IHC CK(AE-1) NR 0-60 OS/DFS pN0 Yes
Wang Zhou LNMM RT-PCR MUC1 NR 0-36 OS pN0 Yes
Abbreviations: LMMM lymph node micrometastases, IHC immunohistochemistry, CK cytokeratin, DFS disease- free survival, OS overall survival, NR not reported,
RT-PCR Reverse transcription-polymerase chain reaction. MUC1, polymorphic epithelial mucin 1
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significance of molecular tumor-cell detection in LN for
the outcomes of DFS (HR, 2.34; 95 % CI, 1.67-3.27;
p < 0.00001). Statistical heterogeneity was not de-
tected (I2 = 30 %, χ2 = 2.87, df = 2, P = 0.24) (Fig. 3).
Discussion
This systematic review and meta-analysis showed that
the molecular detection of tumor cells in regional lymph
nodes is associated with an increased risk of disease re-
currence and poor survival in patients with negative
pathologic lymph node status NSCLC.
Lung cancer remains the most common cancer in the
world, both in terms of new cases (1.8 million cases,
12.9 % of all cancers) and deaths (1.6 million deaths,
19.4 %) because of the high number of fatal cases [16].
The TNM staging system of lung cancer is widely used
as a guide for predicting the prognosis. The presence of
lymph node metastases along with T and M status repre-
sents the most accurate factor that is currently available
for the prediction of prognosis in patients who undergo
complete surgical resection. However, a significant pro-
portion of patients with early stage NSCLC who undergo
potentially curative resections subsequently relapse and
die. This suggests that occult micrometastasis can exist
at the time of surgery; the rate is clearly underestimated
by current clinical staging examinations and conven-
tional histopathologic methods. A nodal micrometastasis
was defined according to the definition of the Inter-
national Union Against Cancer (UICC; i.e. as a single or
small number of tumor cells that are 0.2 mm in dimen-
sion [ITCs] and as tumor deposits < 2.0 mm but greater
than 0.2 mm in dimension [MMs]) [17]. If the UICC
definition was not applied or mentioned explicitly, single
or clustered cells that were detected in molecular ana-
lyses were also considered as occult disease. In this
study, we identified occult micrometastatic tumor cells
in pN0 lymph nodes in half of the patients with com-
pletely resected stage 1 NSCLC using an immunohisto-
chemical staining assay. The patients with lymph node
micrometastasis had a poorer prognosis than the pa-
tients without micrometastasis by univariate or multi-
variate analyses; the prognostic impact was independent
from the TNM staging system [8].
For this meta-analysis, we attempted to closely follow
the recommendations presented by the Cochrane Col-
laboration. We pre-specified a strict study protocol, and
we searched documents from several international con-
ferences, electronic databases and reference research for
relevant trials. The language was not restricted. Eight
documents, which were published worldwide from 1996
to 2011, were included in the meta-analysis. Despite the
number of documents that have been reported and the
Table 2 Demographic data
Author Year LNM+ LNM- HR(LNM+ VS LNM-) 95 %CI(Lower-upper) In(HR) SE(InHR) Outcomes reported
Chun-Dong Gu 2002 22 27 2.12 0.53-8.41 0.75 0.7 OS
Kazuhito Dobashi 1997 14 17 5.1 0.61-42.66 1.63 1.08 OS
B. Passlick 2001 27 125 2.5 1.4-4.6 0.9 0.3 OS
Jakob R. Izbicki 1996 16 51 4.96 1.65-14.87 1.6 0.56 DFS
By Toshihiro Osaki 2002 32 83 1.7 0.57-5.09 0.53 0.56 OS
Kosei Yasumoto 2003 34 182 2.77 0.94-8.17 1.02 0.55 OS
Kosei Yasumoto 2003 34 180 3.06 1.38-6.78 1.12 0.41 DFS
Wang Zhou 2003 16 42 1.84 0.68-4.93 0.61 0.5 OS
Valerie W. Rusch 2011 130 450 1.63 1.13-2.36 0.49 0.19 DFS
Valerie W. Rusch 2011 130 450 1.59 1.13-2.23 0.46 0.17 OS
Fig. 1 Selection diagram for studies
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well-explained risk of patients with LNMM, the prog-
nostic significance of LNMM of patients with NSCLC
has remained highly undetermined. Therefore, we
pooled the analysis of all documents that indicated a
strong evidence of the independent, adverse prognostic
impact of LNMM regarding OS and DFS at the time of
the initial diagnosis of operable NSCLC.
Micrometastases disease is the significant cause of
mortality from solid tumors. Tumor cells that are de-
tected molecularly in the LN of patients with NSCLC
are subjected to one of three fates: death, dormancy, or
proliferation [18]. Most metastatic cells die in this hos-
tile microenvironment [19, 20], or they balance the
growth rates with the death rates [21]. Other cells adapt
by responding to stimuli from the microenvironment.
The poor prognostic significance of LNMM regarding
OS and DFS likely occurs because the tumor cells that
survive in the LN can completely escape dormancy and
begin to proliferate as soon as they reach their destin-
ation. Alternately, some of the tumor cells begin to pro-
liferate later after an unknown situation that permits
them to overcome inhibitory effects at the metastatic
site [18]. Therefore, these tumor cells become viable
micrometastases rather than shed tumor cells with a
limited life span. Lymph node micrometastasis, as well
as overt lymph node metastasis, does not necessarily
reflect lymphogenous spread, but it can signal the early
phase of hematogenous systemic tumor cell dissemination.
This meta-analysis has shown that the detection of
lymph node occult micrometastatic tumor cells is
helpful in predicting recurrence and the prognosis of pa-
tients with early stage NSCLC. It would also be possible
to select patients who might benefit from adjuvant
chemotherapy., postoperative adjuvant chemotherapy is
not a routine standard therapy for patients with com-
pletely resected NSCLC because of its unreliable results
for the improvement of prognosis. However, numerous
trials, including two randomized trials [22, 23], of induc-
tion chemotherapy for stage 3A NSCLC have shown that
it was feasible and indicated higher response rates and a
survival advantage. Additionally, LNMM patients with a
minimal amount of residual tumor could respond better
to chemotherapy.
This study has limitations because of the sample size. Al-
though we contacted each author to supplement the miss-
ing data, the number of included studies was insufficient to
perform some of the preplanned subgroup analyses, and
only 3 subgroup studies were included in our analysis.
Consequently, we could not identify the effect modifiers
that could be attributable to the low statistical power.
Conclusions
In conclusion, there is evidence that molecular tumor cell
detection in regional lymph nodes indicates poor progno-
sis in node-negative NSCLC. Despite a prognostic impact
of tumor cell detection across the applied detection assays,
standardized protocols should be used in future studies
that use standardized end points and adhere to the UICC
definition of tumor cells and micrometastasis. By using
such protocols, it should be clarified within prospective
Fig. 2 Meta-analyses on the association of molecular tumor cell detection in regional lymph nodes with overall survival
Fig. 3 Meta-analysis on the association of molecular tumor cell detection in regional lymph nodes with disease-free survival
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randomized trials whether patients with occult lymph node
disease benefit from adjuvant chemotherapy. Furthermore,
the findings of this study encourage efforts to identify sub-
populations of disseminated cells that put patients at a
particular risk of disease recurrence and poor survival.
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